ArticleJournal of the American Heart Association2017
Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension.
Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Use of Quadruple Therapy in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Systolic blood pressure time-in-target range and kidney outcomes in patients with hypertension: Findings from the STEP trial.Chinese medical journal · 2026Trial
- Systolic Blood Pressure Time in Target Range and Acute Kidney Injury in Patients With Hypertension.Hypertension (Dallas, Tex. : 1979) · 2025Trial
- Trial
- Association of Systolic Blood Pressure Time in Target Range With Cardiovascular Events Among PRECISION Participants.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Trial
- Trial
- Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2022Trial
- Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension.Journal of the American College of Cardiology · 2021Trial
- Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study.Journal of clinical hypertension (Greenwich, Conn.) · 2018Trial
- Long-term SBP time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.American journal of hypertension · 2026Observational
- Asian expert consensus on high-quality hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Time in target range for body mass index and risk of new onset multimorbidity in middle-aged and older adults: a landmark analysis of two prospective cohorts.Journal of global health · 2026Article
- Article
- Physician-led telemedical care enhances blood pressure control in hypertension: a randomized-controlled pilot study (REMOTE-control-HTN).European heart journal open · 2026Article
- Baseline Human Metabolic Profiling and Risk of Death from COVID-19: Conceptualization of Multivariate Prediction Model Development via Retrospective Database Analysis in the United States Department of Veterans Affairs.Journal of clinical medicine · 2026Article
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Development and validation of a deep neural network for predicting coronary heart disease in hypertensive patients using 24-hour ambulatory blood pressure monitoring: a retrospective study.Frontiers in medicine · 2026Article
- A retrospective analysis of systolic blood pressure time in target range among patients in coronary care unit.Scientific reports · 2025Article
- Long-term time in target range for body mass index (BMI) and diabetes incidence: insights from CHARLS.Nutrition & diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidence indicates that reducing systolic blood pressure (BP) to <140 mm Hg improves health outcomes; however, an optimal level has not yet been determined. Many population studies or post hoc analyses suggest a target systolic BP between 120 and 140 mm Hg with increased risk above and below that range. We tested the hypothesis that consistent control of systolic BP between 120 and 140 mm Hg-time in therapeutic range-is a strong determinant of all-cause mortality among US veterans. METHODS AND
resultsA total of 689 051 individuals from 15 Veterans Administration Medical Centers were followed over a 10-year period. Participants were classified as hypertensive, intermediate hypertensive, and normotensive according to the number of elevated BP recordings (>3, 1 or 2, and none, respectively). Time within, above, or below therapeutic range (120-140 mm Hg) was considered in quartiles and related to all-cause mortality. The study population consisted of 54% hypertensive, 19.9% intermediate, and 26.1% normotensive participants; the corresponding mortality rates for the 3 groups were 11.5%, 8%, and 1.9%, respectively (
conclusionsAn inverse and gradual association between time in therapeutic range and all-cause mortality was observed in this large veteran cohort. Consistency of BP control over time is a strong determinant of all-cause mortality, and consistency of BP control should be monitored in everyday clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.